Applied Research Systems Ars Holding N.v.

Human Genome Sciences, Inc.

Other

University of Michigan

Marta Muzio

Alberto Mantovani

Jian Ni

Vishva M Dixit

Francesco Colotta

Ping Feng

Martino Introna

The present invention relates to a novel IRAK-2 protein which is a member of the IL-1 signaling pathway. In particular, isolated nucleic acid molecules are provided encoding the human IRAK-2 protein. IRAK-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting IRAK-2 related disorders and therapeutic methods for treating IRAK-2 related disorders.

Human IRAK-2

The present invention relates to a peptide capable of binding to ICE and/or to enzymes of the ICE family, which peptide consists essentially of the amino acid sequence of SEQ ID NO:1 reported in the Sequence Listing, in which Xaa is selected between Asp and Ala, optionally containing one or more amino acids at its N-terminal and/or C-terminal end. It also relates to the use of the above peptide, for the preparation of pharmaceutical compositions active in pathologies requiring ICE inhibition and/or inhibition of enzymes of the ICE family.

Ice inhibiting peptides

Human IRAK-2 antibodies

A novel interleukin-1 antagonist active against both IL-1.alpha. and IL-1.beta. and DNA encoding same/re described. Antibodies specific for the novel IL-1 antagonist and prophylatic, therapeutic and diagnostic uses of the IL-1 antagonist in pathologies associated with IL-1 production are also described.

Antibodies to intereleukin-1 antagonists

A novel interleukin-1 antagonist active against both IL-1.alpha. and IL-1.beta. and DNA encoding same are described. Antibodies specific for the novel IL-1 antagonist and prophylatic, therapeutic and diagnostic uses of the IL-1 antagonist in pathologies associated with IL-1 production are also described.

DNA encoding interleukin-1 antagonist

It is described a new interleukin-1 antagonist active both against IL-1.alpha. and IL-1.beta., a new DNA sequence encoding the Il-1 antagonist and the method for obtaining a IL-1 antagonist by the recombinant DNA technique; it is also described the prophylactic, therapeutic and diagnostic use of such new IL-1 antagonist in pathologies deriving from the IL-1 production.

Growing community of inventors

Milan, Italy

Marta Muzio